Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Mustang Bio, Inc. MBIO

Healthcare  —  Biotechnology
0.52 (0.01) (1.89%) as of 25 Sep
Market cap
$4.0M
P/E
0.0×
Cash Flow Champion (3y) Insider Buys (last 12m)
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Mustang Bio, Inc. (MBIO) Business Profile

Updated before January 2025

Company Overview

Mustang Bio, Inc. (NASDAQ: MBIO) is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative cell and gene therapies for the treatment of hematologic cancers, solid tumors, and rare genetic diseases. Founded in 2015, Mustang Bio is headquartered in Worcester, Massachusetts, and operates as a subsidiary of Fortress Biotech, Inc. The company is led by a team of seasoned executives and scientists, including CEO Manuel Litchman, M.D., who brings extensive experience in oncology and gene therapy development. Mustang Bio’s mission is to transform the lives of patients by delivering cutting-edge therapies that address unmet medical needs.

Core Business Segments

Mustang Bio focuses on two primary business segments: cell therapy and gene therapy. These segments are supported by a robust pipeline of investigational products aimed at addressing critical medical challenges.

Cell Therapy

Mustang Bio’s cell therapy program is centered on chimeric antigen receptor T-cell (CAR-T) technology. CAR-T therapies are designed to reprogram a patient’s immune cells to target and destroy cancer cells. Key products in this segment include:

  • MB-106: A CAR-T therapy targeting CD20-positive B-cell malignancies, including non-Hodgkin lymphoma and chronic lymphocytic leukemia. MB-106 has shown promising results in early clinical trials.
  • MB-102: A CAR-T therapy targeting CD123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN).

Gene Therapy

Mustang Bio’s gene therapy program focuses on developing treatments for rare genetic diseases. The company leverages cutting-edge gene-editing technologies to address the root causes of these conditions. Key products in this segment include:

  • MB-107 and MB-207: Gene therapies for X-linked severe combined immunodeficiency (XSCID), also known as “bubble boy disease.” MB-107 is designed for newly diagnosed infants, while MB-207 targets patients who have previously undergone hematopoietic stem cell transplantation.

Business Model

Mustang Bio operates on a vertically integrated business model that combines in-house research and development, clinical trials, and manufacturing capabilities. The company generates revenue through licensing agreements, partnerships, and eventual commercialization of its therapies. Mustang Bio’s state-of-the-art manufacturing facility in Worcester, Massachusetts, enables it to produce high-quality cell and gene therapies at scale, ensuring cost efficiency and quality control.

Strategic Direction

Mustang Bio is committed to advancing its pipeline of cell and gene therapies while exploring new opportunities for growth. Key strategic priorities include:

  • Pipeline Expansion: The company aims to broaden its portfolio by developing additional CAR-T and gene therapy candidates.
  • Global Partnerships: Mustang Bio seeks to establish strategic collaborations with academic institutions, research organizations, and pharmaceutical companies to accelerate the development and commercialization of its therapies.
  • Sustainability Goals: Mustang Bio is dedicated to minimizing its environmental footprint by adopting sustainable practices in its operations and manufacturing processes.
  • Regulatory Approvals: The company is focused on securing regulatory approvals for its lead candidates, including MB-106, MB-102, MB-107, and MB-207.

Competitive Landscape

Mustang Bio operates in a highly competitive biopharmaceutical market, facing competition from both established players and emerging startups. Key competitors include:

  • Kite Pharma (a Gilead Sciences company): A leader in CAR-T cell therapy with approved products like Yescarta.
  • Novartis: Known for its CAR-T therapy Kymriah, which targets B-cell acute lymphoblastic leukemia (ALL).
  • Bluebird Bio: A pioneer in gene therapy with a focus on rare genetic diseases.
  • Sangamo Therapeutics: Specializes in gene editing and gene therapy technologies.

Despite the competition, Mustang Bio differentiates itself through its focus on niche indications and its vertically integrated business model.

Risk Factors

Like any biopharmaceutical company, Mustang Bio faces several risks that could impact its operations and financial performance. Key risk factors include:

  • Regulatory Challenges: Delays or failures in obtaining regulatory approvals could hinder the commercialization of Mustang Bio’s therapies.
  • Market Dependence: The company’s success is heavily reliant on the clinical and commercial success of its lead candidates.
  • Supply Chain Disruptions: Any disruptions in the supply chain for raw materials or manufacturing components could delay production timelines.
  • Financial Risks: As a clinical-stage company, Mustang Bio is not yet profitable and relies on external funding to support its operations.

Recent Developments

Mustang Bio has made significant strides in advancing its pipeline and corporate strategy. Recent highlights include:

  • Clinical Trial Progress: The company reported positive interim data from its Phase 1/2 clinical trial of MB-106, demonstrating high response rates in patients with B-cell malignancies.
  • Manufacturing Milestones: Mustang Bio expanded its manufacturing capabilities to support the production of its cell and gene therapies.
  • Partnerships: The company entered into a collaboration with a leading academic institution to develop next-generation CAR-T therapies.
  • Regulatory Updates: Mustang Bio received Orphan Drug Designation from the FDA for MB-107 and MB-207, highlighting the potential of these therapies to address unmet medical needs.

Investment Considerations

Investors considering Mustang Bio should weigh the following strengths and risks:

Strengths

  • Innovative Pipeline: Mustang Bio’s focus on CAR-T and gene therapies positions it at the forefront of medical innovation.
  • Vertically Integrated Model: In-house manufacturing capabilities provide a competitive advantage in terms of cost and quality control.
  • Strong Leadership: The company’s experienced management team brings deep expertise in oncology and gene therapy.

Risks

  • Clinical and Regulatory Uncertainty: The success of Mustang Bio’s therapies is contingent on positive clinical trial outcomes and regulatory approvals.
  • Financial Dependence: As a pre-revenue company, Mustang Bio relies on external funding, which may not always be readily available.
  • Market Competition: The biopharmaceutical industry is highly competitive, with numerous players vying for market share.

Conclusion

Mustang Bio, Inc. is a promising player in the biopharmaceutical industry, with a strong focus on cell and gene therapies for cancer and rare genetic diseases. While the company faces challenges typical of clinical-stage biotech firms, its innovative pipeline, vertically integrated model, and strategic partnerships position it for long-term success. As Mustang Bio continues to advance its therapies through clinical trials and regulatory processes, it has the potential to make a significant impact on the lives of patients and deliver value to investors.